Literature DB >> 27488438

Klebsiella pneumoniae bloodstream infection, antimicrobial resistance and consumption trends in Ireland: 2008 to 2013.

M Brady1, R Cunney2,3, S Murchan2, A Oza2, K Burns2,4.   

Abstract

This study aimed to describe the epidemiology and antimicrobial resistance trends of Klebsiella pneumoniae bloodstream infection (BSI) in Ireland, in conjunction with national antimicrobial consumption data, during the period 2008 to 2013. A retrospective cohort study of K. pneumoniae BSI cases was conducted, based on notifications from Irish microbiology laboratories to the Health Protection Surveillance Centre (HPSC). In total, 1942 K. pneumoniae BSI cases were identified over 6 years, with 310 reported in 2008 and 326 reported in 2013. From 2008 to 2013, the proportion of isolates resistant to co-amoxiclav (24 % versus 29 %), piperacillin-tazobactam (11 % versus 27 %), third generation cephalosporins (3GC) (11 % versus 21 %), fluoroquinolones (13 % versus 21 %) and gentamicin (11 % versus 17 %) increased overall, concurrent with increasing national rates of antimicrobial consumption in Ireland (acute hospitals: 35.87 versus 39.77 defined daily doses (DDD) per 100 bed days used (BDU); and community: 6.38 versus 7.85 DDD per 1000 inhabitants per day (DID)). Enhanced data on the patient's admission route was available for 735 (38 %) cases. Overall, 51 % (n = 378) were categorised as 'acquired in the reporting hospital'. The all-cause mortality was 20 %, with 115 deaths, 101 (88 %) of whom died within 30 days of blood culture sampling date. K. pneumoniae is the second most common cause of Gram-negative BSI in Ireland, with most cases healthcare-associated and an all-cause mortality of 20 % reported in this study. Annual increases in resistance to different antimicrobial classes and in a multi-drug resistant phenotype have been observed, concurrent with increasing national broad spectrum antimicrobial consumption. These trends portend a risk to patient outcomes and highlight the urgency for individual prescribers to evaluate their antimicrobial prescribing habits in hospitals, long-term care and community settings.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27488438     DOI: 10.1007/s10096-016-2727-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Molecular epidemiologic analysis of multiresistant Klebsiella pneumoniae isolates from a pediatric hospital.

Authors:  José Cabrita; Mónica Oleastro; Maria Manuel Lopes; Rosa Barros; Isabel Peres; Ilda Pires
Journal:  Clin Microbiol Infect       Date:  1999-02       Impact factor: 8.067

2.  First identified case of VIM-producing carbapenem-resistant Klebsiella pneumoniae in the Republic of Ireland associated with fatal outcome.

Authors:  A R Prior; C Roche; M Lynch; S Kelly; K O'Rourke; B Crowley
Journal:  Euro Surveill       Date:  2010-12-16

3.  Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes.

Authors:  Eleni Mouloudi; Euthymia Protonotariou; Alexia Zagorianou; Elias Iosifidis; Areti Karapanagiotou; Tatiana Giasnetsova; Agoritsa Tsioka; Emmanuel Roilides; Danai Sofianou; Nikoleta Gritsi-Gerogianni
Journal:  Infect Control Hosp Epidemiol       Date:  2010-10-25       Impact factor: 3.254

4.  Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections.

Authors:  D Ben-David; R Kordevani; N Keller; I Tal; A Marzel; O Gal-Mor; Y Maor; G Rahav
Journal:  Clin Microbiol Infect       Date:  2011-07-01       Impact factor: 8.067

5.  Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health.

Authors:  Kathryn E Holt; Heiman Wertheim; Ruth N Zadoks; Stephen Baker; Chris A Whitehouse; David Dance; Adam Jenney; Thomas R Connor; Li Yang Hsu; Juliëtte Severin; Sylvain Brisse; Hanwei Cao; Jonathan Wilksch; Claire Gorrie; Mark B Schultz; David J Edwards; Kinh Van Nguyen; Trung Vu Nguyen; Trinh Tuyet Dao; Martijn Mensink; Vien Le Minh; Nguyen Thi Khanh Nhu; Constance Schultsz; Kuntaman Kuntaman; Paul N Newton; Catrin E Moore; Richard A Strugnell; Nicholas R Thomson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

6.  Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.

Authors:  Mario Tumbarello; Pierluigi Viale; Claudio Viscoli; Enrico Maria Trecarichi; Fabio Tumietto; Anna Marchese; Teresa Spanu; Simone Ambretti; Francesca Ginocchio; Francesco Cristini; Angela Raffaella Losito; Sara Tedeschi; Roberto Cauda; Matteo Bassetti
Journal:  Clin Infect Dis       Date:  2012-07-02       Impact factor: 9.079

7.  Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance.

Authors:  Cheol-In Kang; Sung-Han Kim; Ji-Whan Bang; Hong-Bin Kim; Nam-Joong Kim; Eui-Chong Kim; Myoung-don Oh; Kang-Won Choe
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

Review 8.  Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors.

Authors:  R Podschun; U Ullmann
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

9.  Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns.

Authors:  Wen-Chien Ko; David L Paterson; Anthanasia J Sagnimeni; Dennis S Hansen; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Joseph G McCormack; Victor L Yu
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

10.  Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence.

Authors:  Alexandre R Marra; Sérgio B Wey; Adauto Castelo; Ana Cristina Gales; Ruy Guilherme R Cal; José R do Carmo Filho; Michael B Edmond; Carlos Alberto P Pereira
Journal:  BMC Infect Dis       Date:  2006-02-14       Impact factor: 3.090

View more
  5 in total

1.  Effective Photodynamic Therapy with Ir(III) for Virulent Clinical Isolates of Extended-Spectrum Beta-Lactamase Klebsiella pneumoniae.

Authors:  Constanza Núñez; Annegrett Palavecino; Iván A González; Paulina Dreyse; Christian Erick Palavecino
Journal:  Pharmaceutics       Date:  2021-04-22       Impact factor: 6.321

2.  Tigecycline application in a 3-month-old infant with multiple drug resistant Klebsiella pneumonia: a case report.

Authors:  Cheng Peng; Xiaofeng Wang; Jiangwei Zhang; Yi Jiang; Xinlin Hou
Journal:  Gut Pathog       Date:  2018-06-22       Impact factor: 4.181

3.  A 7-year surveillance of the drug resistance in Klebsiella pneumoniae from a primary health care center.

Authors:  Guogang Li; Sheng Zhao; Sipei Wang; Yingqian Sun; Yangxiao Zhou; Xinling Pan
Journal:  Ann Clin Microbiol Antimicrob       Date:  2019-11-09       Impact factor: 3.944

Review 4.  Potential targets for next generation antimicrobial glycoconjugate vaccines.

Authors:  Francesca Micoli; Paolo Costantino; Roberto Adamo
Journal:  FEMS Microbiol Rev       Date:  2018-05-01       Impact factor: 16.408

5.  Exploring the Genome and Phenotype of Multi-Drug Resistant Klebsiella pneumoniae of Clinical Origin.

Authors:  João Anes; Daniel Hurley; Marta Martins; Séamus Fanning
Journal:  Front Microbiol       Date:  2017-10-23       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.